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CNS receptora b s t r a c t
Several known D2 pharmacophores have been explored as templates for identifying ligands with multiple
binding affinities at dopamine and serotonin receptors considered as clinically relevant receptors in the
treatment of neuropsychiatric diseases. This approach has resulted in the identification of ligands that
target multiple CNS receptors while avoiding others associated with deleterious effects. In particular,
compounds 11, 15 and 22 may have potential for further development as antipsychotic agents as they
favorably interact with the clinically relevant receptors including D2R, 5-HT1AR, and 5-HT7R. We have also
identified the pair of compounds 11 and 10 as high affinity D2R ligands with and without SERT binding
affinities, respectively. These differential binding profiles endow the pair with the potential for evaluating
SERT contributions to antipsychotic drug activity in animal behavioral models. In addition, compound 11
has no significant affinity for 5-HT2CR and binds only moderately to the H1R, suggesting it may not induce
weight gain or sedation when used clinically. Taken together, compound 11 displays an interesting
pharmacological profile that necessitates the evaluation of its functional and in vivo effects in animal
models which are currently ongoing.1. Introduction
The dopamine D2 receptor (D2R) has long been considered the
target for drug development in schizophrenia and other neuropsy-
chiatric diseases.1 More recently, however, several neuropsychi-
atric illnesses are being viewed as multiple receptor pathological
diseases, meaning that effective drugs designed to treat these
diseases must target several receptors simultaneously.2–6 This
view is supported, for example, by the fact that a neuropsychiatric
disease like schizophrenia manifests at least three different symp-
toms: positive, negative and cognitive symptoms. While blocking
D2R has been associated with treating the positive symptoms,
the negative and cognitive symptoms remain unresolved.7,8 Sev-
eral recent articles have indicated that the negative symptoms of
schizophrenia may be ameliorated by activating the serotonin
5-HT1A receptor (5-HT1AR)9–13 while the cognitive symptoms
may be treated by agents that activate the 5-HT1AR and antagonizethe 5-HT7 receptor (5-HT7R).14–18 Taken together, we hypothesize
that a drug that interacts appropriately with these receptors
should have improved therapeutic outcomes over several currently
marketed drugs for treating schizophrenia. Indeed, one of the most
recent drugs introduced on the market, lurasidone, targets
multiple receptors including D2, 5-HT2A, 5-HT7 and 5-HT1A, and
has found clinical utility not only in treating the positive
symptoms of schizophrenia but also in producing improvement
in cognitive symptoms, and is even prescribed for bipolar
depression.19,20
Our laboratory has been involved in multi-receptor targeting as
possible treatment options for CNS diseases over the years.2,21,22 In
this article, we explored different modifications to pharmacophoric
groups (Fig. 1) present in ligands that have high affinity for CNS
receptors or elaborated structurally similar functionalities to such
pharmacophores. The working hypothesis was that by modifying
the arylalkyl groups attached to the amino groups in the pharma-
cophores shown in Figure 1, it was possible to broaden the affinity
of a target compound to other CNS receptors including the D2R,
5-HT1AR, 5-HT7R and SERT. In view of the role of the D2R as a
R = H, n = 3; 28
R = H, n = 4; 29
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Figure 1. Structures of standard drugs and the pharmacophoric groups (R = R1 = H) used in obtaining the target compounds.primary target for drug development against neuropsychiatric
diseases including schizophrenia and bipolar depression, it was
of interest to first obtain agents that had moderate to high affinity
to the D2R (10P Ki 6 250 nM) before introducing structural
features that lead to binding at the other receptors of interest.
We also intended to identify compounds that while binding to
these receptors will simultaneously have low or little affinities at
5-HT2BR, 5-HT2CR and histamine H-1 receptors as these have been
associated with known side effects including valvular heart
disease,23–25 weight gain26–28 and sedation.26–28
2. Chemistry
The pharmacophoric groups (R = R1 = H) in 1, 3, 4 and 5 were
commercially available from Sigma/Aldrich. Pharmacophore 6
was previously synthesized.29–31 To synthesize the target
compounds 7–22, different alkylating agents were required as
depicted in Figure 2. Alkylating groups 28–29 were obtained by
reacting 5-chloropentanoyl chloride or 4-chlorobutanoyl chloride
with 2-aminobenzenethiol as previously reported,21,32 while 30
was synthesized from 2-amino-4-chlorobenzenethiol and
5-chloropentanoyl chloride using the same procedure.
We also previously reported the synthesis of alkylating agent
3121,32 while 32 was obtained by following a literature
procedure.33–37 Briefly, 4-(1H-indol-3-yl)butanoic acid was
reduced by lithium aluminum chloride and the resulting primary
alcohol converted to the iodide (32) using triphenylphosphine
(Ph3P) and iodine in CH2Cl2. The benzoxazole alkylating agent 33
was synthesized following the literature procedure we reported
earlier.38 6-Chlorohexanoyl chloride or 5-chloropentanoyl chloride
were each reacted with 2-aminophenol in the presence of triethy-
lamine (Et3N) and heated to reflux to provide the amide intermedi-
ate which underwent cyclization with polyphosphoric acid (PPA)
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Figure 3. Structures of target3. Results and discussion
The pharmacophoric groups in spiperone (1), the chloro analog
of benperidol (3), haloperidol (5) and the tropane analog of
haloperidol (6) in Figure 1 constituted the group of starting
fragments selected because of their association with high affinity
binding to the D2 receptor.29–31 The flunarizine pharmacophore
(4) was also included for evaluation as flunarizine has been shown
to demonstrate multiple CNS actions.39 We have hypothesized that
by attaching various aryl alkyl groups to these pharmacophores, it
is possible to obtain compounds which can bind to the D2R and
other clinically relevant receptors including 5-HT1AR and 5-HT7R.
In particular, it was of interest to attach aryl (benzothiazole-,
benzoxazole- and indole-) alkyl groups in view of their observed
effects on binding affinity to CNS receptors.21,32,38
The first group of compounds (Fig. 3), 7–11, were obtained by
the alkylation of 1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (2)
with the appropriate arylalkyl group (Schemes 1–4), and their
binding affinity constants are reported in Table 1. Compound 7
showed potent binding to the D2R but only moderate to weak
binding affinities to the 5-HT receptors evaluated. Introduction of
a chloro group onto the benzothiazole ring (8) to explore the effect
of an electron withdrawing group on the ring electron density did
not produce any significant changes in binding affinity. Similarly,
insertion of a carbonyl moiety (9) had no significant effect. Further-
more, replacement of the benzothiazole with either benzoxazole
(10) or indole (11) moieties failed to extend significant increase
in affinity to the 5-HT receptors. Based on their overall binding
profile at these receptors, group 1 compounds could, in general,
be classified as showing selectivity to the D2 and D3 receptors
(Ki range 10–32 nM) while binding to the D4R is mixed, with 11
showing the highest binding affinity (Ki = 1.6 nM) and compound
8 the lowest (Ki = 1512 nM). Compounds 8 and 9 bind with moder-
ate affinity to the 5-HT1AR (Ki = 102 and 103 nM, respectively) and
combined with their high affinity to the D2R, could serve as useful
agents for further exploration.
5-Chloro-1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one,
the pharmacophore of 3, was next selected for alkylation and
resulted in compounds 12–15. These along with compounds 16
and 17 constitute group 2 analogs (Fig. 4, Schemes 1–4). Synthesis
and subsequent screening produced the binding affinity data
reported in Table 2. Compound 12 has about 9-fold lower affinity
to the D2R (Ki = 215 nM) compared to the corresponding analog in
group 1 (compound 7) suggesting that the triazaspiro[4.5]decan-4-
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Scheme 1. Synthesis of target compounds 7, 8, 12, 16, 18, 19, and 21. Reagents and conditions: (i) K2CO3, KI, CH3CN/DME, reflux, 12–15 h.pharmacophore 3. Indeed, compounds 13–15 which utilize
pharmacophore 3 display lower binding affinity compared to the
corresponding analogs in group 1. In addition, the binding of


















Scheme 2. Synthesis of target compounds 9, 13, 17 and 22. ReagenWe also evaluated two piperazine analogs utilizing the 1-(bis
(4-fluorophenyl)methyl)-piperazine, pharmacophore from 4.
Alkylating this group with the previous benzothiazole-alkyl groups
produced compounds 16 and 17 which bind to the D2R with

























































































Scheme 4. Synthesis of target compounds 11 and 15. Reagents and conditions: (i) K2CO3, CH3CN, reflux, 12–15 h.
Table 1
Binding affinity (Ki nM/pKi ± SE) of group 1 compounds at selected DA and 5-HT receptorsa
Compound Ki (nM)/pKi ± SE
D2 D3 D4 5-HT1A 5-HT2A 5-HT7
7 24.0/7.62 ± 0.04 32.0/7.49 ± 0.06 132.0/6.88 ± 0.04 195/6.71 ± 0.07 >10,000/N/A 626.0/6.2 ± 0.1
8 18.0/7.74 ± 0.08 499.0/6.3 ± 0.07 1512.0/5.8 ± 0.1 102.0/6.99 ± 0.06 1123.0/5.8 ± 0.1 1598.0/5.8 ± 0.1
9 25.0/7.59 ± 0.07 18.0/7.75 ± 0.04 162.0/6.79 ± 0.05 103.0/6.99 ± 0.04 3720.0/5.43 ± 0.04 518.0/6.29 ± 0.05
10 10.0/7.99 ± 0.04 21.0/7.68 ± 0.05 118.0/6.93 ± 0.04 382/6.42 ± 0.07 MTA 1511/5.8 ± 0.1
11 22.0/7.65 ± 0.06 31.0/7.5 ± 0.1 1.6/8.81 ± 0.05 376.0/6.42 ± 0.07 982.0/6.01 ± 0.07 >10,000
Spiperone 0.16 ± 0.02b 0.32 ± 0.04c 1.4 ± 0.5c 17.2 ± 3.8d 1.1 ± 0.07e 110 ± 17f
N/A = Not available. Data points without SE have errors below 20% of the mean.





f Ref. 44.the other group 2 analogs, D2R binding affinity was lower along
with weak affinity to the 5-HT receptors evaluated. Overall, the
group 2 analogs have D2R binding affinity constants below
250 nM, varying moderate to high binding affinities at the D3
(Ki = 33–233 nM) and D4 (Ki = 16–1710 nM) receptors and
relatively poor binding to the 5-HT receptors.
Compounds in group 3 (Fig. 5) are obtained by alkylating
4-chlorophenyl piperidinol or tropanol pharmacophores from 5
and 6. We have previously shown that these pharmacophores
can be manipulated to control their CNS receptor binding
profiles.29–31 Using the previously synthesized benzothiazole- or
benzoxazole-linked alkyl groups, 4-chlorophenyl piperidinol was
targeted for alkylation to produce compounds 18–20 (Schemes
1–3). These compounds were synthesized and screened at the
same receptors as before and the results are reported in Table 3.
Apart from compound 19 with moderate binding affinity(Ki = 201 nM) none of the other four analogs meets the D2 binding
criterion. Other than compound 18 which binds with relatively
high affinities at the 5-HT1AR and 5-HT7R (Ki = 34.0 and
189.0 nM, respectively), there were no significant improvements
in binding at the 5-HT receptors. Finally, the tropane analogs 21
and 22 were synthesized and similarly screened. Compound 21
binds with high affinity at the D2R and D3R (Ki = 44.0 and 13 nM,
respectively) but binds poorly to the D4R and 5-HT receptors. Com-
pound 22 on the other hand binds with moderate affinity to the
D2R (Ki = 180.0 nM) and with even higher affinity at the 5-HT7R
(Ki = 80.0 nM). Overall, the group 3 analogs have high to moderate
binding to the D2R and variable binding affinities to the 5-HT
receptors evaluated.
In view of the fact that D2R ligands with favorable interactions
at 5-HT1AR, 5-HT2AR, 5-HT7R and the serotonin transporter (SERT)
have potential utility as effective agents for schizophrenia and
An = A1; 14



































Figure 4. Structures of target compounds in group 2.
Table 2
Binding affinity (Ki nM/pKi ± SE) of group 2 compounds at DA and 5-HT receptorsa
Compound Ki (nM)/pKi ± SE
D2 D3 D4 5-HT1A 5-HT2A 5-HT7
12 215.0/6.67 ± 0.05 163.0/6.79 ± 0.06 671.0/6.17 ± 0.06 1162.5/N/A >10,000/N/A 286.0/6.54 ± 0.06
13 217.0/6.66 ± 0.04 64.0/7.2 ± 0.04 1710.0/5.77 ± 0.07 252.0/6.6 ± 0.04 1564.0/5.81 ± 0.04 127.0/6.9 ± 0.05
14 95.0/7.02 ± 0.06 109.0/6.96 ± 0.06 841.0/6.08 ± 0.05 611/6.21 ± 0.05 3392.0/5.47 ± 0.05 313.0/6.5 ± 0.06
15 134.0/6.87 ± 0.07 53.0/7.3 ± 0.1 16.0/7.79 ± 0.06 MTA MTA 111.0/6.95 ± 0.08
16 195.0/6.71 ± 0.07 33.0/7.5 ± 0.1 68.0/7.17 ± 0.05 MTA 519.0/6.28 ± 0.05 778.0/6.1 ± 0.1
17 159.0/6.8 ± 0.07 233.0/6.6 ± 0.1 1217.0/5.91 ± 0.05 MTA 1082.0/5.97 ± 0.07 562.0/6.3 ± 0.1
Benperidol* 0.027b 0.29 ± 0.02c 0.066b N/A 1.2d N/A
N/A = Not applicable or not available.









X = S, n = 3; Compound 18
X = S, n = 4; Compound 19








An = A1; 21
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Figure 5. Structures of target compounds in group 3.
Table 3
Binding affinity (Ki nM/pKi ± SE) of group 3 compounds at DA and 5-HT receptorsa
Compound Ki (nM)/pKi ± SE
D2 D3 D4 5-HT1A 5-HT2A 5-HT7
18 763.0/6.12 ± 0.05 28.0/7.55 ± 0.09 163.0/6.79 ± 0.04 34.0/7.47 ± 0.04 168.0/6.78 ± 0.04 189.0/6.72 ± 0.08
19 201.0/6.7 ± 0.08 291.0/6.54 ± 0.06 140.0/6.85 ± 0.06 771.0/6.11 ± 0.08 4255.0/5.37 ± 0.06 983.0/N/A
20b 438 ± 28 942 ± 200 229 ± 49 3153 ± 368 5970 ± 1189 MTA
21 44.0/7.35 ± 0.03 13.0/7.89 ± 0.6 432.0/6.36 ± 0.09 274.0/6.60 ± 0.06 >10,000 1009/6.0 ± 0.07
22 180.0/6.74 ± 0.07 16.0/7.79 ± 0.07 508.0/6.29 ± 0.09 MTA MTA 80.0/7.1 ± 0.08
Haldol 5* 0.89/9.05 ± 0.30 2.5/8.61 ± 0.05 10.0/7.98 ± 0.28 3600/5.44 ± 0.03 120.0/6.91 ± 0.02 1100/5.95 ± 0.13
Analog 6*,b 1.6 ± 0.14 5.1 ± 3.0 5.3 ± 0.99 27.7 ± 8.0 30.9 ± 6.0 ND
ND = Not determined. N/A = Not applicable. Data points without SE have errors below 20% of the mean.
a MTA = Missed 50% threshold inhibition.
* Previously reported in Refs. 2,48.
b Only Ki values provided.bipolar depression for example, compounds 7–11, 14, 15, 21 and
22 were selected for further evaluation at other receptors
associated with improved pharmacological profile and the results
are recorded in Table 4. The binding affinities of these compounds
at other receptors associated with the undesirable side effects
(5-HT2B, 5-HT2C and H1 receptors) are also reported.
We have hypothesized that compounds which simultaneously
interact with the D2R and, for example, either the 5-HT7R or SERT,have the potential to augment the effectiveness of primarily single
receptor agents used in the treatment of schizophrenia or bipolar
depression. Evaluation of the data in Table 4 shows that
compounds 8 (D2R and 5-HT1AR), 9 (D2R and 5-HT1AR), 11 (D2R
and SERT), 15 (D2R and SERT), and 22 (D2R, 5-HT7R and SERT)
may have potential utility as hits in the development of agents
for the treatment of schizophrenia and bipolar depression, depend-
ing on their functional status. In addition, while both compounds
Table 4
Binding affinity (Ki nM/pKi ± SE) of selected compounds at CNS receptorsa and their c logP valuesb
Receptor Ki (nM)/pKi ± SE
7 8 9 10 11 14 15 21 22
D2R 24/7.62 ± 0.04 18/7.74 ± 0.08 25/7.59 ± 0.07 10/7.99 ± 0.04 22/8.86 ± 0.06 95/7.02 ± 0.06 134/8.57 ± 0.07 44/7.35 ± 0.03 180/6.74 ± 0.07
5HT1AR 195/6.71 ± 0.07 102/6.99 ± 0.06 103/6.99 ± 0.04 382/6.42 ± 0.07 376/6.4 ± 0.1 611/6.21 ± 0.05 MTA 274/6.60 ± 0.06 MTA
5HT2AR >10K 1123/5.8 ± 0.1 3720/5.43 ± 0.04 MTA 982/7.65 ± 0.06 3392/5.47 ± 0.05 MTA >10K MTA
5HT2BR 122/6.91 ± 0.06 36/7.44 ± 0.08 1578/5.8 ± 0.1 905/6.04 ± 0.08 202/6.69 ± 0.08 515/6.29 ± 0.06 51/7.29 ± 0.07 342/6.47 ± 0.06 758/6.12 ± 0.09
5HT2CR MTA 614/6.21 ± 0.08 MTA MTA MTA MTA MTA 4623/5.34 ± 0.09 MTA
5HT7R 626/6.2 ± 0.1 1598/5.8 ± 0.1 518/6.29 ± 0.05 1511/5.82 ± 0.09 >10K 313/6.5 ± 0.06 111/6.95 ± 0.08 1009/6.0 ± 0.07 80.0/7.1 ± 0.08
SERT MTA 3056/5.51 ± 0.06 284/6.55 ± 0.07 MTA 10.0/8.33 ± 0.05 386/6.41 ± 0.06 25/7.6 ± 0.04 180/6.74 ± 0.08 54.0/8.33 ± 0.05
H1R 504/8.93 ± 0.07 263/6.56 ± 0.06 ND 535/6.27 ± 0.09 273/6.56 ± 0.07 510/6.3 ± 0.1 255/6.61 ± 0.06 187/6.73 ± 0.08 1028/5.99 ± 0.08
cLogP 2.48 4.37 3.35 2.57 3.51 4.47 5.42 5.48 5.20
ND = Not determined.
a MTA = missed 50% threshold inhibition.
b cLogP values were estimated using ChemDraw 12.0.11 and 10 bind with high affinities to D2R, 11 binds with high
affinity to SERT but 10 is without significant affinity to SERT. This
differential binding profile endows the pair with the potential for
evaluating SERT contributions in animal behavioral studies.
Furthermore, compound 11 has the desirable profile of no signifi-
cant affinity for 5-HT2CR and only moderate binding to the H1R.
Since the compounds are designed to target CNS receptors, we
also estimated some of the key physicochemical characteristics
including their c logP valuesusingChemDrawversion12 as reported
in Table 4. Apart from compounds 15, 21 and 22 all the other
compounds have estimated c logP values below 5.0. Compound 11,
which displays themost interesting binding affinity profile,was fur-
ther compared with haloperidol and spiperone and the results indi-
cate compound 11 (logP = 3.52; c logP = 3.51; tPSA = 47.61)
compares favorably with haloperidol (logP = 3.49; c logP = 3.85;
tPSA = 40.54) and spiperone (logP = 2.78; c logP = 2.82;
tPSA = 52.65) in terms of their lipophilicity (c logP/logP) and
topological polar surface area (tPSA) values. Overall, both the
pharmacological and physicochemical profiles of these compounds
suggest further evaluation of their functional activities at the
respective receptors and in vivo animal testing to further ascertain
their true potentials as leads for preclinical examination.
4. Conclusion
By modifying the arylalkyl groups attached to various CNS phar-
macophores, we have demonstrated that receptor binding profiles
of these agents can be obtained that could form the basis of iden-
tifying multi-receptor targeting ligands. Several of the compounds
have desirable multi-receptor binding profiles to receptors of inter-
est. In particular, compounds 11, 15 and 22 may have potential
utility as leads for further optimization to treat schizophrenia
and bipolar disorders depending on their functional status. We
have also identified compounds 11 and 10 as high affinity D2R
ligands with and without SERT binding affinities, respectively,
which suggests that they may have a great potential for evaluating
SERT contributions in animal behavioral studies. Compound 11 has
no significant affinity for 5-HT2CR and binds only moderately to the
H1R suggesting little or no induction of sedation or weight gain. In
addition, compound 11’s physicochemical characteristics as
calculated by ChemDraw, are consistent with drugs that cross
the BBB and elicit their pharmacological properties in the CNS.
5. Methods
5.1. Reagents and general procedures
Melting points were determined on a Gallenkamp (UK)
apparatus and are uncorrected. 1H NMR spectra were obtainedon a Varian 300 MHz Mercury Spectrometer. Elemental analyses
were carried out by Atlantic Microlab, Inc., Norcross, GA, and are
within 0.4% of theory unless otherwise noted. Flash chromatogra-
phy was performed on Combi-Flash (Teledyne Isco) using RediSep
normal phase silica columns. N,N-dimethylformamide was
distilled from CaSO4 and stored over 4 Å molecular sieves. Starting
materials were obtained from either Sigma–Aldrich or VWR and
were used without further purification.
5.2. General procedure for the synthesis of alkylating agents
(28–30)
To a solution of 2-aminothiophenol (5 g, 39.9 mmol) or
2-amino-4-chlorobenzenethiol in toluene (100 mL), 5-chlorobu-
tanoyl chloride or 5-chloropentanoyl chloride (43.9 mmol) was
added drop wise over a 15 min period during which an off-white
precipitate was formed. After the reaction mixture was stirred at
room temperature (rt) overnight, water (100 mL) was added, the
two layers were separated and the aqueous layer was extracted
with EtOAc (2  100 mL). The combined organic extract was
washed with water (100 mL) and saturated NaCl solution
(100 mL), dried over Na2SO4 and concentrated in vacuo. The crude
product was purified on Combiflash using EtOAc/Hexanes, to yield
2-(3-chloropropyl)benzo-[d]thiazole 28 or 2-(4-chlorobutyl)benzo
[d]thiazole 29 as an oily liquid or 5-chloro-2-(4-chlorobutyl)
benzo[d]thiazole (30) as a solid.
5.2.1. 2-(3-Chloropropyl)benzo[d]thiazole (28)
Oily liquid, yield: 72%, 1H NMR (CD3OD): d 8.14 (d, 1H,
J = 4.1 Hz), 8.02 (d, 1H, J = 4.1 Hz), 7.72–7.59 (m, 2H), 3.64–3.57
(m, 2H), 3.38–3.28 (m, 2H), 1.95–1.86 (m, 2H).
5.2.2. 2-(4-Chlorobutyl)benzo[d]thiazole (29)
Oily liquid, yield 56%, 1H NMR (CDCl3): d 7.98–7.95 (m, 1H),
7.85e7.82 (m, 1H), 7.48–7.42 (m, 1H), 7.37–7.32 (m, 1H), 3.60
(t, 2H, J = 7.5 Hz), 3.15 (t, 2H, J = 7.5 Hz), 2.09–1.97 (m, 2H),
1.95–1.90 (m, 2H).
5.2.3. 5-Chloro-2-(4-chlorobutyl)benzo[d]thiazole (30)
Solid, yield: 89%, mp: 110 C, 1H NMR (CDCl3): d 7.95 (d, 1H,
J = 2.1 Hz), 7.74 (d, 1H, J = 8.1 Hz), 7.35–7.32 (dd, 1H, J = 1.8,
6.6 Hz), 3.56 (t, 2H, J = 6.0 Hz), 3.15 (t, 2H, J = 7.5 Hz), 2.08–2.00
(m, 2H), 1.96–1.89 (m, 2H).
5.3. Procedure for the synthesis of 3-(4-iodobutyl)-1H-indole
(32)
The synthesis of 3-(4-iodobutyl)-1H-indole followed literature
procedures.36,49 To a solution of indole-3-butyric acid (2 g,
9.8 mmol) dissolved in THF (30 mL) and cooled to 0 C was added
portionwise LiAlH4 (2.24 g, 59.0 mmol, 6 equiv) in THF. Themixture
wasallowedtowarmto roomtemperaturewith stirring for18 h. The
reaction mixture was cooled to 0 C and a saturated solution of
Na2SO4 (20 mL) was added in a dropwise manner over the period
of 30 min. The resulting white precipitate was filtered, the filtrate
was washed with EtOAc (2  100 mL), the pooled organic phase
was washed with water (50 mL) and saturated brine solution
(50 mL), dried over anhydrous Na2SO4 and the solvent removed
under reduced pressure. The crude product 3-(4-hydroxybutyl)-
1H-indolewasobtainedas a colorless solidandused for thenext step
without further purification (1.70 g), Yield: 91%, mp: 32–33 C.
1HNMR (300 MHz, CDCl3): d 7.95 (s, 1H), 7.60 (d, 1H, J = 7.8 Hz),
7.36–7.33 (m, 1H), 7.21–7.08 (m, 2H), 6.97 (s, 1H), 3.67 (t, 2H,
J = 6.3 Hz), 2.79 (t, 2H, J = 7.5 Hz), 1.84–1.63 (m, 4H). To a stirred
solution of triphenylphosphine (4.46 g, 17.0 mmol) and imidazole
(1.58 g, 17.0 mmol) in dichloromethane (DCM) (45 mL) cooled to
0 C, was added I2 (4.32 g, 17.0 mmol) and the reaction mixture
was stirred at 0 C for 30 min. Thereafter, a solution of 3-(4-hydrox-
ybutyl)-1H-indole (2.30 g, 12.15 mmol) in DCM (5 mL) was added,
the reaction mixture was allowed to warm to rt with stirring for
12 h, then filtered and the filtrate was washed with hexane
(2  100 mL). The combined organic solution was washed with
water (100 mL) and saturated brine (80 mL) before being dried over
anhydrous Na2SO4. The solvent was removed under reduced
pressure and the crude product was purified on CombiFlash using
EtOAc/hexanes as eluent. The pure product 3-(4-iodobutyl)-1H-
indole was isolated as an oily liquid (2.40 g), Yield: 66%. 1H NMR
(300 MHz, CDCl3): d 7.91 (s, 1H). 7.59 (d, 1H, J = 8.1 Hz), 7.35
(d, 1H, J = 8.1 Hz), 7.22–7.17 (t, 1H, J = 6.9 Hz), 7.12 (m, 1H), 6.97
(d, 1H, J = 2.1 Hz), 3.22 (t, 2H, J = 6.9 Hz), 2.84 (t, 2H, J = 6.9 Hz),
1.96–1.76 (m, 4H).
5.4. General alkylation procedure for compounds (7–12)
The procedure previously reported by us was followed.16 A mix-
ture of 2-(3-chloropropyl)benzo[d]thiazole (28) (1.3 mmol), or the
appropriate alkylating agent (29 or 30), the appropriate amine
(1.33 mmol), KI (100 mg), K2CO3 (13.3 mmol), and CH3CN (15 mL)
was heated to reflux for 12–24 h. The reaction progress was
monitored by TLC and at completion, the mixture was cooled to
rt, solvent removed, the resulting residue loaded onto a cartridge
and purified by flash chromatography using EtOAc/hexane (9:1)
to give the pure desired products. The hydrochloride salts where
necessary were prepared by dissolving each pure compound in
an appropriate solvent, adding excess ethereal HCl solution,
removing solvent under reduced pressure, and recrystallizing the
residue from an appropriate solvent.
5.4.1. 8-(4-(Benzo[d]thiazol-2-yl)butyl)-1-phenyl-1,3,8-
triazaspiro[4.5]decan-4-one (7)
Yield: 32.4%, mp: 184–185 C, 1H NMR (300 MHz, DMSO-d6): d
8.58 (s, 1H), 8.03–8.00 (m, 1H), 7.93–7.89 (m, 1H), 7.48–7.43 (m,
1H), 7.39–7.34 (m, 1H), 7.22–7.16 (t, 2H, J = 10.2 Hz), 6.81 (d, 2H,
J = 7.8 Hz), 6.73–6.68 (t, 1H, J = 7.2 Hz), 4.54 (s, 2H), 3.16–3.11 (t,
2H, J = 7.8 Hz), 2.71–2.46 (m, 6 Hz), 2.39–2.34 (t, 2H, J = 7.2 Hz),
1.90–1.80 (m, 2H), 1.60–1.51 (m, 4H). Calcd for: C24H28N4OS0.2H2-
O: C, 67.96; H, 6.65; N, 13.21; Found: C, 67.95; H, 6.70; N, 12.94.
5.4.2. 8-(4-(5-Chlorobenzo[d]thiazol-2-yl)butyl)-1-phenyl-1,3,8-
triazaspiro[4.5]decan-4-one (8)
Yield: 40%, mp: 206–208 C, 1HNMR (300 MHz, DMSO-d6): d
8.57 (s, 1H), 8.08–8.05 (d, 1H, J = 9.0 Hz), 8.00 (d, 1H, J = 1.8 Hz),
7.46–7.42 (dd, 1H, J = 1.8, 8.4 Hz), 7.22–7.17 (dd, 2H, J = 1.2,
7.2 Hz), 6.83–6.81 (d, 1H, J = 8.1 Hz), 6.74–6.69 (t, 1H, J = 7.5 Hz),
4.55 (s, 2H), 3.29 (s, 2H), 3.18–3.13 (t, 2H, J = 7.5 Hz), 2.71–2.62
(m, 4H), 2.39–2.34 (t, 2H, J = 7.5 Hz), 1.87–1.82 (m, 2H),1.55–1.51 (m, 4H). Calcd for C24H27ClN4OS0.1H2O: C, 63.10; H,
6.00; N, 12.26; Found: C, 62.85; H, 6.06; N, 12.17.
5.4.3. 8-(4-(Benzo[d]oxazol-2-yl)butyl)-1-phenyl-1,3,8-
triazaspiro[4.5]decan-4-one (10)
Yield 56.2%, mp: 176–177 C, 1H NMR (300 MHz, DMSO-d6): d
8.57 (s, 1H), 7.67–7.61 (m, 2H), 7.33–7.30 (m, 2H), 7.19 (t, 2H,
J = 7.5 Hz), 6.81 (d, 1H, J = 7.8 Hz), 6.70 (t, 1H, J = 7.2 Hz), 4.54 (s,
2H), 2.96–2.94 (t, 2H, J = 7.8 Hz), 2.70–2.50 (m, 6H), 2.35
(t, 2H, J = 7.5 Hz), 1.87–1.78 (m, 2H), 1.60–1.50 (m, 4H). Calcd for:
C24H28N4O20.24H2O: C, 70.52; H, 6.90, N, 13.71; Found: C, 70.52;
H, 6.85; N, 13.68.
5.4.4. 8-(4-(1H-Indol-3-yl)butyl)-1-phenyl-1,3,8-triazaspiro[4.5]
decan-4-one (11)
Yield: 48.9%, mp: 208–210 C, 1H NMR (300 MHz, DMSO-d6): d
10.79 (s, 1H), 9.03 (s, 1H), 7.52–6.80 (m, 10H), 4.61 (s, 2H),
3.70–3.17 (m, 4H), 2.80–2.62 (m, 6H), 2.00–1.50 (m, 6H). Calcd
for: C25H30N4O0.3H2O: C, 73.61; H, 7.56; N, 13.73; Found: C,
74.00; H, 7.62; N, 13.39.
5.4.5. 1-(1-(4-(Benzo[d]thiazol-2-yl)butyl)piperidin-4-yl)-5-
chloro-1H-benzo[d]imidazol-2(3H)-one (12)
Yield: 24.2%, mp: 186–188 C, 1H NMR (300 MHz, DMSO-d6): d
11.00 (s, 1H), 8.04–8.01 (m, 1H), 7.9–7.90 (m, 1H), 7.49–7.46 (dd,
1H, J = 1.5, 5.7 Hz), 7.40–7.35 (m, 1H), 7.18 (d, 1H, J = 8.1 Hz),
6.99–6.95 (dd, 2H, J = 2.1, 9.6 Hz), 4.14–4.00 (m, 1H), 3.12 (t, 2H,
J = 7.2 Hz), 2.95 (d, 2H, J = 10.5 Hz), 2.35 (t, 2H, J = 7.5 Hz), 2.29–
2.20 (m, 2H), 2.02–1.94 (m, 2H), 1.86–1.81 (m, 2H), 1.62–1.52
(m, 4H). Calcd for: C23H25ClN4OS0.66 H2O: C, 61.00; H, 5.56; N,
12.37; Found: C, 60.99; H, 5.57; N, 11.99.
5.4.6. 1-(1-(4-(Benzo[d]oxazol-2-yl)butyl)piperidin-4-yl)-5-
chloro-1H-benzo[d]imidazol-2(3H)-one (14)
Yield: 34%, mp: 189–191 C, 1HNMR (300 MHz, DMSO-d6): d
7.67–7.63 (m, 2H), 7.35–7.30 (m, 2H), 7.18 (d, 1H, J = 8.1 Hz),
7.00–6.95 (m, 2H), 4.14–4.4.02 (m, 1H), 2.96 (t, 4H, J = 7.2 Hz),
2.34 (t, 2H, J = 6.9 Hz), 2.27–2.22 (m, 2H), 1.98 (t, 2H, J = 10.5
Hz), 1.80 (m, 2H), 1.61–1.49 (m, 4H). Calcd for: C23H25ClN4O2-




Yield: 40%, mp: 95–97 C, 1HNMR (300 MHz, CDCl3): d 9.16 (s,
1H), 7.99 (s, 1H), 7.62 (d, 1H, J = 7.5 Hz), 7.36 (d, 1H, J = 8.7 Hz),
7.22–7.07 (m, 4H), 7.02 (d, 2H, J = 8.7 Hz), 4.40–4.30 (m, 1H),
3.12 (d, 2H, J = 11.7 Hz), 2.80 (t, 2H, J = 7.2 Hz), 2.48 (t, 4H,
J = 6.9 Hz), 2.15 (t, 2H, J = 12.3 Hz), 1.83–1.68 (m, 6H). Calcd for:
C24H27ClN4O0.18EtOAc: C, 65.69; H, 6.20; N, 12.77; Found: C,
65.66; H, 6.45; N, 12.34.
5.4.8. 2-(4-(4-(Bis(4-fluorophenyl)methyl)piperazin-1-yl)butyl)
benzo[d]thiazole dihydrochloride(16)
Yield: 54.4%, hydroscopic, 1H NMR (300 MHz, CD3OD): d 8.01–
7.98 (m, 1H), 7.94–7.91 (m, 1H), 7.70–7.60 (m, 4H), 7.58–7.53
(m, 1H), 7.49–7.44 (m, 1H), 7.13 (t, 4H, J = 8.7 Hz), 5.14–5.00 (m,
1H), 3.60–3.52 (m, 4H), 3.32–3.25 (m, 10H), 2.04–1.82 (m, 4H).
Calcd for: C28H31Cl2F2N3S0.75H2O: C, 59.62; H, 5.81; N, 7.45;
Found: C, 59.45; H, 5.41; N, 7.28.
5.4.9. 1-(Benzo[d]thiazol-2-yl)-5-(4-(bis(4-fluorophenyl)
methyl)piperazin-1-yl)pentan-1-one dihydrochloride (17)
Yield: 63.7%, hygroscopic, 1H NMR (300 MHz, CDCl3): d 13.10 (s,
1H), 8.15 (d, 1H, J = 7.8 Hz), 7.98–7.92 (m, 5H), 7.60–7.50 (m, 2H),
7.20–7.10 (m, 4H), 5.16 (s, 1H), 4.34 (br s, 2H), 4.14–4.05 (m, 2H),
3.68–3.58 (m, 2H), 3.35 (br s, 2H), 3.21 (br s, 2H), 2.06–1.94 (br s,
6H). Calcd for: C29H31Cl2F2N3OSH2O: C, 57.52; H, 5.66; N, 6.94;
Found: C, 57.63; H, 5.60; N, 6.66
5.4.10. 1-(3-(Benzo[d]thiazol-2-yl)propyl)-4-(4-chlorophenyl)
piperidin-4-ol hydrochloride (18)
Yield: 27%, mp 199–200 C, 1H NMR (DMSO-d6): d 10.89 (s, 1H),
8.07 (d, J = 7.8 Hz, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.38–7.52 (m, 6H),
5.59 (s, 1H), 3.42–3.46 (m, 2H), 3.16–3.26 (m, 6H), 2.37–2.45 (m,
2H), 2.27–2.35 (m, 2H), 1.74–1.79 (m, 2H). Calcd for: C21H24Cl2N2-
OS: C, 59.57; H, 5.71; N, 6.62; Found: C, 59.54; H, 5.71; N, 6.62.
5.4.11. 1-(4-(Benzo[d]thiazol-2-yl)butyl)-4-(4-chlorophenyl)
piperidin-4-ol (19)
Yield: 17.5%, mp: 143–145 C, 1H NMR (CDCl3): d 7.79–7.94 (m,
1H), 7.86–7.83 (m, 1H), 7.48–7.42 (m, 3H), 7.38–7.29 (m, 3H), 3.16
(t, 2H, J = 7.8 Hz), 2.98–2.84 (m, 2H), 2.60–2.52 (m, 4H), 2.30–2.18
(m, 2H), 2.00–1.90 (m, 2H), 1.80–1.72 (m, 5H).Calcd for: C22H25ClN2-
OS: C, 65.90; H, 6.28; N, 6.91; Found: C, 65.56; H, 6.17; N, 6.91.
5.4.12. 1-(4-(Benzo[d]oxazol-2-yl)butyl)-4-(4-chlorophenyl)
piperidin-4-ol (20)
Yield: 49.5%, mp: 134–135 C, 1H NMR (CDCl3): d 7.67–7.64 (m,
1H), 7.49–7.46 (m, 1H), 7.43 (d, 2H, J = 9.0 Hz), 7.32–7.28 (m, 4H),
2.97 (t, 2H, J = 7.8 Hz), 2.80 (dd, 2H, J = 2.4, 8.7 Hz), 2.47 (t, 2H,
J = 7.8 Hz), 2.37 (dd, 2H, J = 2.1, 9.6 Hz), 2.14–2.04 (m, 2H),
1.97–1.92 (m, 2H), 1.73–1.64 (m, 5H). Calcd for: C22H25ClN2O2:
C, 68.65; H, 6.55; N, 7.28; Found: C, 68.39; H, 6.36; N, 7.10.
5.5. General procedure for the synthesis of compounds 21 and
22
Amixture of alkylating agent (29 or 31) (2.5 mmol), 3-(4-chloro-
phenyl)-8-azabicyclo[3.2.1]octan-3-ol (680 mg, 2.85 mmol), K2CO3
(700 mg, 5.07 mmol) in DME (10 mL) was heated to reflux under
N2 for 16 h. The mixture was diluted with EtOAc (400 mL), washed
with brine (50 mL) and the organic layer was dried over Na2SO4,
and filtered. The filtrate was concentrated in vacuo to dryness and
column chromatographed on silica gel to afford the desired product.
The productwas converted into theHCl salt, followed by crystalliza-
tion fromMeOH–Et2O to afford the pure HCl salt.
5.5.1. Synthesis of 8-(4-(benzo[d]thiazol-2-yl)butyl)-3-(4-
chlorophenyl)-8-azabicyclo[3.2.1]octan-3-ol hydrochloride (21)
Yield 37%, mp: 198–200 C, 1H NMR (DMSO-d6): 10.92 (1H, br
s), 8.04 (1H, d, J = 8.1 Hz), 7.92 (1H, d, J = 8.1 Hz), 7.77 (2H, d,
J = 8.4 Hz), 7.47 (1H, m), 7.40 (1H, m), 7.34 (2H, d, J = 8.4 Hz),
3.98 (2H, m), 3.15 (2H, m), 3.00 (2H, m), 2.63 (2H, m), 2.46 (4H,
m), 2.08 (2H, m), 1.93 (6H, m). Calcd for C24H28Cl2N2OS0.4H2O:




Yield 43%, mp: 202–204 C, 1H NMR (DMSO-d6): 10.46 (1H, br
s), 8.24 (2H, m), 7.73 (2H, d, J = 8.7 Hz), 7.64 (2H, m), 7.36 (2H, d,
J = 9.0 Hz), 5.47 (1H, s), 4.30 (2H, m), 3.35 (4H, m), 3.14 (2H, m),
3.00 (2H, m), 2.57 (2H, m), 2.09 (2H, m), 1.88 (4H, m), 1.75 (2H,
m). Calcd for C25H28Cl2N2O2S0.8H2O: C, 59.36; H, 5.58; N, 5.54;
Found: C, 59.46; H, 5.82; N, 5.57.
5.5. Receptor binding studies
Binding affinities reported in Tables 1–4 were conducted by the
National Institute of Mental Health Psychoactive Drug Screening
Program (NIMH-PDSP).5 Details of the methods and radioligandsused for the binding assays are available on the NIMH PDSP web-
site at http://pdsp.med.unc.edu/UNC-CH%20Protocol%20Book.pdf.
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